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The difficult thing about the future is that it is so hard to 
predict. After the Second World War, the availability of 
vaccines and antibiotics and the successes of improved 
hygiene and public health policies led to such a dramatic 
fall in mortality that in 1969 the US Surgeon General 
claimed that "we can close the book on infectious 
diseases." In hindsight, his prediction of the future was 
utterly wrong—infectious diseases are back with a 
vengeance. Nearly 25% of the annual deaths worldwide 
are directly related to pathogens [38]; multidrug-resistant 
tuberculosis and HIV/AIDS are on the rise worldwide; and 
Staphylococcus and Enterococcus strains in Western 
hospitals are becoming increasingly resistant to 
antibiotics. In addition, the rapid spread of new 
pathogens, such as the SARS (severe acute respiratory 
syndrome) and West Nile viruses, has shown the frailty of 
global public health, which is further affected by tourism 
and trade. Experts in security and public health also worry 
that publicly available scientific information and advanced 
genetic technologies could be misused to create weapons 
for bioterrorism. 
To overcome these threats to human health, research on 
pathogenic microbes and the development of new 
diagnostics, vaccines and therapeutic strategies remains 
an important task at the beginning of the twenty-first 
century. It is in this context that we conducted our 
Foresight study, 'Future Trends and Challenges in 
Pathogenomics', as part of the EU-funded ERA-NET 
project PathoGenoMics, to provide an overview of current 
and future trends and challenges in the field of genomic 
research on pathogenic microorganisms. Clearly, a 
Foresight study is not a crystal ball to peek into the future, 
but it does allow the identification of important trends in 
science, as well as perceived gaps in research, and 
places them in the context of future challenges for public 
health. 
We pursued a dual approach, conducting both a survey 
with national and international experts in the field of 
pathogenomics and an extensive literature research. For 
the survey, we developed questionnaires and emailed 
them to 329 experts in research on human-pathogenic 
microorganisms and related fields. We received 65 replies 
and 40 completed questionnaires; an overall reply rate of 
19.8 % and a return rate of 12.2 %, which are satisfactory 
[15; 52; 48]. For the literature review, we used both 
academic search engines and direct access to scientific 
journals. The search was conducted using the following 
keywords and combinations of terms: pathogenomics, 
infectious disease, public health, bacteria, fungi, 
bioweapons, bioterrorism, human pathogen. From the 
3,542 resulting hits, we selected 186 review articles, 
abstracts and press releases, and analysed them for 
further trends and challenges in research, threats to 
public health and current bottlenecks in commercial drug 
and vaccine development. 
One clear trend is that, according to Weinstock [53], the 
study of pathogenic microorganisms is undergoing major 
changes, triggered by the availability of whole genome 
sequences, new screening technologies, proteomics, 
comparative genomics and bioinformatics. These 
technologies, in combination with conventional methods of 
serology and the cultivation of strains, are becoming 
increasingly important for the classification and 
evolutionary analysis of microorganisms [32]. Molecular 
fingerprinting, single-nucleotide polymorphism analyses 
and molecular epidemiology allow the study of the 
molecular processes during infection, including 
inflammation and host immune responses, and the 
function of cell-surface proteins and bacterial secretion 
systems. In vivo expression analyses and new bioimaging 
techniques to measure gene expression and protein 
transport now enable scientists to investigate the role of 
individual genes during infection in real time [19]. All these 
technological advances and their application in 
microbiology contribute to a better understanding of host–
microbe interactions and immune responses on the 
molecular and physiological level. 
According to Hatfull & Jacobs [30] there has also been 
much progress in studying the genetics of infection and 
pathogenesis, as well as the communication between 
microorganisms. But much more needs to be known; 
Parsek & Fuqua [43] highlight the importance of research 
on surface-associated pathogens, such as biofilms or 
planktonic cultures, which has so far been neglected. 
Such knowledge will help researchers to understand the 
complex interactions between microbes, whereas 
modelling of stress factors in the environment can 
elucidate interactions between microbes and host factors. 
In this context, the identification of virulence factors and 
secreted effectors that modulate the human immune 
system, such as exotoxins, small molecules or 
extracellular enzymes, is another important goal. To meet 
the increasing problem of antibiotic resistance, basic 
research should also concentrate on the detection and 
analysis of mobile pathogenic elements and resistance 
transfer through genomic islands [28]. Another important 
development is the fusion of cell biology with 
microbiology, which will be of great importance for 
studying the in situ expression of genes [47]. Denning and 
colleagues [17] note recent advances in microscopy, such 
as multidimensional imaging, laser-scanning microscopy, 
epifluorescence microscopy and fluorescent light-based 
imaging, while stressing the importance of microscopy 
and histopathology. The need for better cooperation 
between basic and clinical research, particularly when 
collecting epidemiological data or devising new or more 
efficient therapies, is also a related concern. Here, 
nanobiotechnology will also gain importance for analytical 
approaches in chip technology, as will systems biology for 
the analysis of experimental data (see following). 
In general, these new technologies are needed to 
understand more clearly the nature of infection, so as to 
devise new strategies against infectious organisms. An 
important goal will be the identification of specific target 
genes for DNA chips used in clinical diagnostics and for 
the development of new antibiotics and vaccines. 
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According to Weinstock [53], the discovery of such target 
genes will not be a major problem, rather the 
development of high-throughput methods to test the 
efficacy of new therapeutics. Furthermore, he forecasts 
that candidate genes will be identified and will be in 
commercial use long before scientists are able to 
understand fully the molecular mechanisms of infection 
and pathogenesis. 
Another important research area, particularly in light of 
new and re-emerging diseases, concerns the dynamics of 
microbe populations and the effects of environmental 
factors on these populations. These include the natural 
reservoirs of pathogens and their geographical 
distributions, differentiation between generalists and 
specialists among human-pathogenic agents, and 
microbe–environment interactions [13]. According to 
Woolhouse and colleagues [59], population biology will 
explain the evolutionary dynamics of pathogenic 
specialization and the stress responses of microbes. 
Woolhouse [58] also emphasizes the importance of 
studying routes of pathogen transmission through vectors 
(such as arthropods) and direct (for example, physical 
contact) or indirect contact (such as through food). 
Ultimately, this epidemiological research will contribute to 
the early identification of novel and re-emerging diseases 
caused by bacteria, fungi and multi-resistant bacterial 
strains. In this context, the understanding of immune 
selection and the impact of vaccination and antibiotic 
intervention on microbial populations are future 
challenges for research [25]. So far, such studies have 
mostly used pure bacterial cultures, which of course do 
not reflect reality. DeLong [16] therefore stresses the 
need for microbial population genomics to characterize 
uncultivatable bacterial and fungal species, and the 
interactions between various microbial populations. 
A literature review by Cleaveland and colleagues [13] 
identified 1,415 species of organisms known to be 
pathogenic to humans, including 538 bacteria and 
rickettsia and 307 fungi, and according to Rappuoli [45], 
"dozens of new infectious diseases are expected to 
emerge in the coming decade." Viruses, particularly RNA 
viruses, seem to emerge most rapidly. In this context, 
Lederberg [32] stresses the need to understand 
evolutionary strategies of pathogenic microbes that 
facilitate their re-emergence and the emergence of new, 
unknown pathogens due to their rapid reproduction and 
enormous potential for genetic variation. Mutation, genetic 
variation, recombination and horizontal gene transfer of 
pathogenic islands are keys to the evolution of pathogens 
[28] which still have to be understood. 
Of course, these trends and developments in basic 
research have to be put into context with current and 
future challenges for public health (see following titled 
'Challenges for interdisciplinary research on human-
pathogenic microorganisms'). These encompass 
demographic changes in ageing populations, and the 
effects of globalization, population growth and migration—
whose social, ecological and economic factors and their 
interplay are still poorly understood [42]. Most experts in 
our survey identified HIV and the spread of multidrug-
resistant tuberculosis in Eastern Europe as major 
problems for public health—some experts estimate that 
about one-third of the world is infected with 
Mycobacterium tuberculosis [23]. Other problems 
mentioned in the expert survey included malaria, SARS, 
monkey pox and sexually transmitted, respiratory and 
diarrhoeal diseases. The greatest challenge is what Chan 
and colleagues [12] describe as the substantial 
differences between developed and developing countries 
with respect to the burden of infectious diseases. The 
authors estimate that about 40% of the population of the 
developing world are infected with at least one pathogenic 
organism compared with only 2% in the developed world. 
In many developing countries, socio-economic factors, 
such as poverty, crowding and poor hygiene, represent 
major risks for the transmission of infectious diseases and 
accordingly for global public health [56]. Man-made 
ecological changes, such as deforestation and pollution, 
and the effects of land use or water storage, also 
influence the biological diversity and distribution of 
parasitic and infectious diseases [26]. Chan and 
colleagues [12] estimate that global climatic conditions in 
particular are the most important determinants for 
pathogen distribution, but so far few studies of this 
phenomenon are available. Irrespective of global climatic 
conditions, simple weather changes influence the 
emergence of infectious diseases and their vectors [51], 
for example the El Niño phenomenon in the Southern 
Pacific, or floods that cause outbreaks of malaria or 
waterborne disease such as cholera [38]. Altekruse and 
colleagues [1] therefore identify food-borne and water-
borne diseases as major threats to public health. Morens 
and colleagues [38] also describe an increase in zoonotic 
and vector-borne diseases due to environmental factors 
and recent man-made interventions. This trend is further 
accelerated by antibiotic overuse in agriculture, which 
may increase the proliferation of bacterial and fungal 
diseases. 
The rapid spread of SARS in 2003 from China to the rest 
of the world showed that infectious diseases can no 
longer be seen as problems of developing countries, now 
that global trade and tourism enable the rapid distribution 
of infectious organisms. Mangili & Gendreau [35] thus 
predict an increase in airborne, food-borne, vector-borne 
and zoonotic diseases caused by the increasing ease and 
affordability of air travel. Cleaveland and colleagues [13] 
therefore stress human behaviour as the main factor for 
the spread of infectious diseases. 
There are also many aspects in the medical system itself 
that pose a threat to public health. The most important 
problem is the lack of hygiene in hospitals and the 
resulting increase of so-called nosocomial, or hospital-
acquired, diseases [7]. New technologies, such as 
transplantation medicine, immunosuppressive therapies 
and prosthetic devices, have also raised the prevalence of 
chronic or polymicrobial infections [18]. Their increasing 
number [6], and the deaths caused by mycoses [37], 
should be taken very seriously. Further problems in the 
public-health system itself include a decreasing number of 
effective antibiotics, insufficient guidelines and 
surveillance methods for antibiotic resistance, and a 
general decrease in research on anti-infectives [17]. 
Lederberg [32] criticizes especially the misuse of 
antibiotics and the popularity of antibacterial products, 
which further contribute to the spread of multi-drug 
antimicrobial resistance [24], particularly among 
Mycobacterium tuberculosis and Staphylococcus aureus. 
Methicillin-resistant S. aureus, vancomycin-resistant 
Enterococci and drug-resistant Gram-negative bacteria 
such as Klebsiella and Enterobacter spp. have already 
become major problems in many hospital settings [33; 
31], which has led Cars & Nordberg [9] to speculate about 
the possibility of a post-antibiotic era. 
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Finally, the potential misuse of scientific information and 
genetic engineering for bioterrorism and biowarfare is 
worrying public health and security experts [36]. It 
remains to be seen whether freely available information 
on genetics and genomic research is sufficient for the 
development of biological weapons [44]. The World 
Health Organization [54] accordingly addresses the need 
for action plans to counteract potential bioterrorist attacks; 
indeed, Woodall [57] criticizes that there is no such 
international body to investigate the sudden emergence of 
infectious diseases. 
Predominantly, what is needed to prevent re-emerging 
infectious diseases from turning into an epidemic or 
pandemic is a global surveillance network and vaccination 
strategy [34], especially for childhood immunization [4]. 
Both developed and developing countries must therefore 
increase their participation rates in vaccination 
programmes by improving health education and public 
policy. In addition to these general measures, Cangelosi 
and colleagues [8] recommend more effective monitoring 
of pathogens in the environment, which would allow 
researchers to understand their incidence and 
persistence. Regarding novel infectious diseases, 
Guillemot and colleagues [27] address the identification of 
natural sources and zoonotic reservoirs as the basis of 
preventing or controlling such outbreaks. According to 
Enserink [22], better coordination between labs and public 
health organizations by global alert networks such as the 
Global Outbreak Alert and Response Network (GOARN) 
would lead to earlier identification of novel pathogens. 
Education, sanitation and water supply in developing 
countries must be improved to counteract the increasing 
internationalization of health risks brought about by 
infectious disease [42]. The US National Institute of 
Allergy and Infectious Diseases [41] stresses the need for 
food safety, animal-control programmes and clean water 
and sewers, because many gastrointestinal pathogens 
are transmitted through water. Moreover, it is essential to 
develop comparative risk-assessment strategies to set 
national and global health priorities [39]. Forecasting 
systems, computer-modelling techniques and disease 
epidemiology are other measures to assess the impact of 
disease outbreaks [29]. 
From the perspective of basic research, the identification 
of factors leading to chronic and secondary diseases and 
the evolution of antibiotic resistance are most 
fundamental challenges [11]. On a more practical level, 
rapid, sensitive and robust diagnostic tools are needed in 
addition to improved disease-management strategies and 
infrastructures as part of an early response strategy to 
tackle infectious diseases. This does not, however, 
replace the imperative to develop new antibiotics and 
make better use of existing ones. According to Bonhoeffer 
and colleagues [2], the alternation of different antibiotics, 
the evaluation of single and multiple antibiotic therapies 
and the rational use of antibiotics in general are 
necessary to reduce bacterial resistance. 
Although the development of new antibiotics and vaccines 
remains an important public-health imperative, 
pharmaceutical companies have little interest in this 
research area. The European Federation of 
Pharmaceutical Industries and Associations (EFPIA; 
Brussels, Belgium) notes that the European industry has 
been undergoing radical changes during the past decade, 
triggered by the increasing costs for R&D and marketing 
[20]. This has led to a rising number of company mergers 
and takeovers and a greater focus on drugs to treat 
chronic and abundant diseases in mainly affluent 
populations. Because the development of new antibiotics 
and vaccines is a long and costly process and will 
ultimately find only a limited market [55], research in this 
area is not very attractive for many pharmaceutical 
companies. Spellberg and colleagues [50] stress that out 
of 506 drugs that were in late-stage clinical testing in 
2004, only six were new antibacterials. Similarly, there is 
only a small number of biotech companies that develop 
vaccines or antifungal drugs [5; 3] 
Nevertheless, there are promising and commercially 
attractive areas of research on anti-infectives and 
vaccines. Sheridan [49], for instance, describes innovative 
approaches that use recombinant DNA techniques to 
develop new vaccines. Combination vaccines to prevent 
complex syndromes might be useful, along with new 
methods of vaccine application and antibody preparation, 
which are often faster and cheaper than vaccine 
development itself [4; 10]. Bröker [5] also forecasts a 
rising market for products on the basis of reverse 
vaccinology, genetic vaccination and recombinant 
antigens, and for conjugate and therapeutic vaccines. 
According to EFPIA [20], outsourcing such projects by 
subcontracting to smaller companies, especially in the 
area of pre-clinical research or toxicological analysis, 
could render antibiotic and vaccine development 
sufficiently beneficial for both the pharmaceutical and 
biotech industries. Finally, Cockerill & Smith [14] expect a 
greater market for genomic-based diagnostics and 
screening technologies. 
However, an important step towards a better fit between 
industry's interests and public health needs would be 
more cooperation between public-health authorities, 
clinicians, affected communities and pharmaceutical 
companies. Hence, governmental support such as the 
reduction of administrative barriers [21], public–private 
partnerships as advocated by organizations such as the 
WHO [46], partnerships with small and medium biotech 
companies, and new business models to encourage the 
development of new drugs [40], will be needed to meet 
the threat of infectious diseases. 
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Important challenges for basic research 
 
Methods  
• Automated high-throughput methods (microarray technology)  
• Genomics, transcriptomics, metabolomics and proteomics  
• Improvement of serology, spectroscopy, chromatography and microscopy  
• In vivo approaches (animal models, bioimaging, real-time PCR)  
• Novel technologies (for example, microfluids, siRNA, multiplex assays)  
• Whole-genome sequencing and bioinformatics 
 
Understanding ways of infection 
• Comparative and functional genomics  
• Factors of virulence and resistance (mobile pathogenic elements)  
• Host switching and antigen diversity (genome plasticity)  
• Immune response (defensins, inflammation)  
• Role of surface proteins 
 
Understanding pathogenesis 
• Communication between species (biofilm, intestinal linings)  
• Effects of DNA methylation and identification of conserved DNA regions  
• Factors and mechanisms of pathogenicity (secretion systems)  
• Host–microbe interaction  
• In-host competition  
• SNP analysis and molecular epidemiology 
 
Diagnostics 
• Chronic infections and chronic inflammation  
• Development of specific antibodies  
• Identification and classification of human-pathogenic bacteria and fungi  
• Identification of toxins, small molecules and allergenic compounds  
• Specific DNA arrays to identify species in polymicrobial cultures 
 
Clinical importance 
• Development of new diagnostic and therapeutic agents  
• Evaluation of effects of chemotherapeutics (such as antibiotics)  
• Creation and extension of databases  
• Link between diagnostics and therapy (individualized medicine)  
• Rapid, sensitive, cheap and standardized diagnostics  
• Validation of diagnostics and molecular methods  
• Target identification (new vaccines, antimicrobial targets) 
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Challenges for interdisciplinary research on human-pathogenic microorganisms 
 
Epidemiology 
• Commensal bacterial flora and opportunistic infections  
• Lifestyle of humans  
• Routes of transmission  
• Spread of pathogens  
• Transmission bottlenecks  
• Vector analysis 
 
Ecology and environment 
• Ecological niches and natural reservoirs  
• Geographical distribution  
• Host range  
• Microbe–environment interaction 
 
Evolution and taxonomy 
• Identification and classification of clinical species  
• Intra-host evolution  
• Phylogenetic derivation 
 
Population dynamics and selection pressure 
• Cultivation-independent genome analyses  
• Dynamics of antibiotic resistance  
• Immune selection  
• Impact of vaccination and antibiotic intervention  
• Interaction between clonal communities  
• Understanding mechanisms of generalists and specialists  
• Understanding microbial diversity 
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